OBJECTIVES/AIMS:

This is an open-label trial of the safety of interferon gamma-1b (IFN-γ) and its effect on frataxin levels and neurologic measures in 12 children with Friedreich ataxia.

MATERIALS AND METHODS:

Interferon gamma-1b was administered via subcutaneous injection three times weekly. The dose increased from 10 to 50 mcg/m2 during the first four weeks and then remained at 50 mcg/m2

Read More: Open-label pilot study of interferon gamma-1b in Friedreich ataxia